February 6, 2020
Mitsubishi Chemical Holdings Corporation
Condensed Consolidated Financial Information
for the Third Quarter of the Fiscal Year Ending March 31, 2020
1. Business Results for the Third Quarter of the Fiscal Year Ending March 31, 2020 ("FY2019") (Business period: April 1, 2019 to December 31, 2019)
Millions of Yen | |||
The Third Quarter of | The Third Quarter of | ||
the Current Fiscal Year | the Previous Fiscal Year | ||
("FY2019") | (""FY2018") | ||
April 1, 2019 - | April 1, 2018 - | ||
December 31, 2019 | December 31, 2018 | ||
(1) Results of Operations: | |||
Sales revenue | 2,730,767 | 2,870,415 | |
Core operating income* | 181,037 | 264,817 | |
Operating income | 160,568 | 268,055 | |
Income before taxes | 144,724 | 263,199 | |
Net Income | 108,280 | 206,425 | |
Net income attributable to owners of the parent | 76,272 | 165,988 | |
Comprehensive income | 93,063 | 190,777 |
*Core operating income is calculated as operating income excluding certain gains and expenses attributable to non- recurring factors.
(Yen) | |||
Earnings per share - Basic | 53.71 | 116.67 | |
- Diluted | 49.54 | 107.68 | |
(2) Segment Information: | |||
[Sales Revenue by Business Segment] | |||
Performance Products | 821,092 | 869,829 | |
Chemicals | 825,992 | 975,391 | |
Industrial Gases | 628,255 | 512,426 | |
Health Care | 321,947 | 360,417 | |
Others | 133,481 | 152,352 | |
Total | 2,730,767 | 2,870,415 | |
[Core Operating Income (Loss) by Business Segment] | |||
Performance Products | 54,425 | 63,316 | |
Chemicals | 38,729 | 107,765 | |
Industrial Gases | 66,503 | 42,076 | |
Health Care | 20,785 | 54,379 | |
Others | 8,642 | 4,752 | |
Elimination and corporate | (8,047) | (7,471) | |
Total | 181,037 | 264,817 |
1
Millions of Yen | ||
As of December 31, 2019 | As of March 31, 2019 | |
(3) Financial Position: | ||
Total assets | 5,413,105 | 5,572,508 |
Total equity | 2,039,018 | 2,025,854 |
Equity attributable to owners of the parent | 1,391,888 | 1,377,947 |
Ratio of equity attributable to owners of the parent | 25.7 | 24.7 |
to total assets (%) | ||
Millions of Yen | ||
The Third Quarter of | The Third Quarter of | |
the Current Fiscal Year | the Previous Fiscal Year | |
("FY2019") | ("FY2018") | |
April 1, 2019 - | April 1, 2018 - | |
December 31, 2019 | December 31, 2018 | |
(4) Cash Flows: | ||
Net cash provided by (used in) operating activities | 337,737 | 276,736 |
Net cash provided by (used in) investing activities | (114,958) | (816,157) |
Net cash provided by (used in) financing activities | (294,294) | 568,807 |
Cash and cash equivalents at the end of the period | 245,348 | 309,951 |
Notes:
- Mitsubishi Chemical Holdings Corporation has classified the businesses of LSI Medience Corporation (LSIM) and its subsidiaries and affiliate as discontinued operations, based on the exchange all of its shares in LSIM. Therefore, sales revenue, core operating income, operating income and income before taxes in the consolidated financial results of the third quarter of the previous fiscal year and the current fiscal year encompass continuing operations and exclude discontinued operations.
-
In the nine months ended December 31, 2019, the impairment loss of ¥17,037 million for goodwill related to pharmaceutical formulation materials business in the Health Care domain was recognized because it was unlikely that investments would be recoverable, as a result of revision of plans in consideration of situation where profitability would plummet amid a deteriorating business environment.
In addition, the carrying amount after impairment presented in the condensed consolidated statement of financial position is ¥15,525 million.
2. Forecasts for the Current Fiscal Year
Millions of Yen | |
FY2019 | |
April 1, 2019 - | |
March 31, 2020 | |
Sales revenue | 3,630,000 |
Core operating income | 210,000 |
Operating income | 182,000 |
Net income attributable to owners of the parent | 81,000 |
(Yen) | |
Earnings per share - Basic | 57.04 |
Note:
The profit and loss forecast for fiscal 2019 has been revised to the above from those announced on November 1, 2019.
2
3. Qualitative Information on Financial Results for the Term
(1) Business Performance
Performance Overview
During the third quarter of fiscal 2019 (April 1 through December 31, 2019), the business outlook remained uncertain for the Mitsubishi Chemical Holdings Group. This was due largely to supply and demand easing for some products, centered on semiconductor and automotive applications, owing to the impact of U.S.-China trade friction.
It was against this backdrop that sales revenue for the term decreased ¥ 139.6 billion, or 4.9%, to
¥2,730.8 billion. Core operating income dropped ¥83.8 billion, or 31.6%, to ¥181.0 billion. As a result of goodwill impairment charges relating to the pharmaceutical formulation materials business in the Health Care domain, operating income declined ¥107.5 billion, or 40.1%, to ¥160.6 billion. Income before taxes was down ¥118.5 billion, or 45.0%, to ¥144.7 billion. Net income attributable to owners of the parent fell ¥89.7billion, or 54.0%, to ¥76.3 billion.
In keeping with an exchange of all of its shares in LSI Medience Corporation, the Group classified the businesses of that consolidated subsidiary and its subsidiaries and affiliate as discontinued. In the third quarter of the year, the Group accordingly classified earnings related to those businesses as discontinued in comparison with the previous corresponding period.
Overview of Business Segments
The overview of financial results by business segment for the third quarter of fiscal 2019 is shown below.
Gains or losses by segment are stated with core operating income which excludes gains or losses from non-recurring factors including losses incurred by business withdrawals, streamlining, and others.
In the following sections, all comparisons are with the same period of the previous fiscal year unless stated otherwise.
Performance Products Segment, Performance Products Domain
Sales revenue decreased ¥48.7 billion, to ¥821.1 billion. Core operating income was down ¥8.9 billion, to ¥54.4 billion.
Functional products sales revenue declined. This was despite higher sales volumes in environment and living solutions, and reflected lower sales volumes in high-performance engineering plastics and other products for advanced moldings and composites, owing to weakened demand, principally in semiconductor and automotive applications.
Performance chemicals sales revenue decreased. This reflected a downturn in what was a favorable
3
market in the first half of the previous year for phenol-polycarbonate chain materials in advanced polymers. This situation offset the impact of higher sales volumes in the absence of the previous year's scheduled maintenance and repairs.
Core operating income decreased primarily due to a drop in market prices for phenol-polycarbonate chain materials in advanced polymers.
Major initiatives in the Performance Products segment during the third quarter of fiscal 2019 included:
- Mitsubishi Chemical Corporation in April 2019 decided to increase the annual production capacity of Soarnol ethylene vinyl alcohol copolymer resin of consolidated subsidiary Noltex LLC by 3,000 metric tons, to 41,000 metric tons. This development, effective in mid-2020, is in response to rising global demand for food packaging materials.
- In June 2019, Mitsubishi Chemical Corporation agreed to transfer the storage media and other global businesses of the Verbatim brand of Mitsubishi Chemical Media Co., Ltd., and assets related to that consolidated subsidiary to CMC Magnetics Corporation. This accord was part of business portfolio reforms under the Mitsubishi Chemical Holdings Group's medium-term management plan. The transaction was completed in December that year.
- MC PET Film Indonesia, a consolidated subsidiary of Mitsubishi Chemical Corporation, in September 2019 decided to lift its polyester film production capacity. The move enables the company to cater to optical applications for displays and to growing demand for multilayer ceramic capacitors and other industrial offerings in response to the expanding use of automotive electronics and a rising number of 5G-compatible base stations. Once the upgrade is completed at the end of 2021, annual production capacity in Indonesia will increase from 20,000 metric tons to 45,000 metric tons.
Chemicals Segment, Industrial Materials Domain
Sales revenue decreased ¥149.4 billion, to ¥826.0 billion. Core operating income was down ¥69.1 billion, to ¥38.7 billion.
In MMA, sales revenue declined amid weaker demand and a downturn in MMA monomer and other markets.
In petrochemicals, while sales volumes increased because of a smaller impact from scheduled maintenance and repairs at the ethylene production facility, prices declined owing mainly to lower raw materials costs and other factors.
Carbon products sales revenue was down, reflecting lower coke prices as a result of reduced raw materials costs as well as because of decreased needle coke sales volumes.
Core operating income decreased mainly attributable to the downturn in MMA monomer and other
4
markets, despite higher sales volumes stemming from the lower impact of the scheduled maintenance and repairs in petrochemicals.
Major initiatives in the Chemicals segment during the third quarter of fiscal 2019 included:
- Japan Polypropylene Corporation, a consolidated subsidiary of Mitsubishi Chemical Corporation, in July 2019 decided to halt production at one polypropylene line at its Kashima Plant, effective April 2020. This move is designed to reinforce the production infrastructure and rationalize amid the construction of a new polypropylene line at the Goi Plant as part of structural reforms to bolster profitability.
- Mitsubishi Chemical Corporation and JXTG Nippon Oil & Energy Corporation established a joint venture in November 2019 to strengthen their collaboration in petroleum refining and petrochemicals operations at the Kashima complex in Ibaraki Prefecture, Japan. It will endeavor to strengthen competitiveness by optimizing manufacturing in petrochemicals and other products. They will also explore chemical recycling technologies to reuse waste plastics as raw materials for petroleum refining and petrochemicals.
Industrial Gases Segment, Industrial Materials Domain
Sales revenue rose ¥115.9 billion, to ¥628.3 billion. Core operating income was up ¥24.4 billion, to ¥66.5 billion.
In industrial gases, sales revenue and core operating income increased, due to including the performance of the European and U.S. businesses acquired in the second half of the previous fiscal year.
Health Care Segment, Health Care Domain
Sales revenue declined ¥38.5 billion, to ¥321.9 billion. Core operating income was down ¥33.6 billion, to ¥20.8 billion.
In pharmaceuticals, sales revenue and core operating income decreased, primarily attributable to lower royalty revenues, despite higher sales volumes in mainly priority products in domestic ethical pharmaceuticals. With regard to royalty revenue from Novartis Pharma AG for Gilenya, a treatment agent for multiple sclerosis, a part of the revenue has not been recognized as sales revenue in accordance with IFRS 15 "Revenue from Contracts with Customers" due to the start of arbitration proceedings since February 2019. Due to the ongoing proceedings, sales revenue has not been recognized and decreased in the third quarter of the year under review.
Major initiatives in the Health Care segment during the third quarter of fiscal 2019 included:
- Life Science Institute, Inc. in August 2019 completed an exchange of shares with PHC Holdings Corporation (PHCHD) after obtaining competition low-related regulatory approval as part of a strategic capital partnership announced in May 2019. PHCHD thereby acquired all shares of LSI
5
Medience Corporation. Life Science Institute obtained a 13.7% stake in PHCHD.
- Life Science Institute, Inc. in July 2019 started clinical trials with the Muse cell-based product CL2020 in patients with spinal cord injuries. Trials previously began for patients with acute myocardial infarction, ischemic stroke, and epidermolysis bullosa. Also in July 2019, cell processing center Tonomachi CPC was authorized to manufacture regenerative medicine products. Life Science Institute plans to apply for marketing approval in fiscal 2020.
- Mitsubishi Tanabe Pharma Corporation in July 2019 received approval from China's National Medical Products Administration for Ederavone (the U.S. brand name is Radicava) for a treatment for amyotrophic lateral sclerosis. The company previously obtained approval in Japan, Korea, the United States, Canada, and Switzerland.
- Mitsubishi Chemical Holdings Corporation commenced a tender offer in November 2019 for Mitsubishi Tanabe Pharma Corporation to expand the drug discovery modality and otherwise tackle a changing medical treatment climate, generating more synergies within the Group. In January 2020, Mitsubishi Chemical Holdings lifted its voting rights ownership ratio in that consolidated subsidiary from 56.4%, to 91.6%, and plans to make that company a wholly owned subsidiary in March 2020.
Others
Sales revenue decreased ¥18.9 billion, to ¥133.5 billion. Core operating income rose ¥3.9 billion, to ¥8.6 billion.
(2) Consolidated Financial Position
Total assets at December 31, 2019, were ¥5,413.1 billion, down ¥159.4 billion from March 31, 2019. This decrease was despite an increase in tangible assets associated with the adoption of the IFRS 16 "Leases," and reflected efforts to constrain cash and cash equivalents and a decline in trade receivables in line with lower sales revenue.
(3) Explanation of Consolidated Financial Results Forecast and Other Forward-Looking Information
In light of recent performance trends, Mitsubishi Chemical Holdings Corporation has revised the forecast that it announced on November 1, 2019 for fiscal 2019, as follows. Also, please refer to the Notice on Revision to Consolidated Financial Results Forecast for the Fiscal Year Ending March 31, 2020, issued today (February 6, 2019).
6
Revision to consolidated financial results forecast for fiscal 2019 (April 1, 2019 - March 31, 2020)
(Unit: Billions of Yen; unless otherwise noted)
Sales | Core | Operating | Net | Net income | Earnings |
operating | attributable to | per share | |||
revenue | income | income | owners of the | ||
income | (Yen) | ||||
parent |
Previous forecast (A) | 3,765.0 | 250.0 | 241.0 | 170.0 | 131.0 | 92.26 |
(announced on November 1, 2019) | ||||||
Revised forecast (B) | 3,630.0 | 210.0 | 182.0 | 122.0 | 81.0 | 57.04 |
Difference (B-A) | (135.0) | (40.0) | (59.0) | (48.0) | (50.0) | ― |
Difference (%) | (3.6) | (16.0) | (24.5) | (28.2) | (38.2) | ― |
Reference: | 3,840.3 | 314.1 | 294.8 | 216.7 | 169.5 | 119.22 |
Results for fiscal 2018 | ||||||
Notes: |
- Net income before taxes: ¥221.0 billion (previous forecast); ¥159.0 billion (revised forecast)
- Core operating income is calculated as operating income (loss) excluding certain gains and expenses attributable to non- recurring factors.
- Sales revenue, core operating income, operating income, and income before taxes encompass continuing operations and exclude discontinued operations.
Sales revenue and core operating income are expected to be lower than the previous forecast. This is because market conditions of MMA, carbon, and other Chemicals segment products will likely be poor, while it is also projected that adjustments will continue for the foreseeable future in demand for products in optical applications for displays and semiconductor and automotive applications.
In the third quarter, management expects sales revenue, net income, and net income attributable to owners of the parent to be lower than previously forecast owing to goodwill impairment charges relating to the pharmaceutical formulation materials business in the Health Care domain.
Forward-Looking Statements
The forward-looking statements are based largely on the Company's expectations and information available as of the date hereof, and are subject to risks and uncertainties which may be beyond the Company's control. Actual results could differ materially due to numerous factors, including, without limitation, market conditions, and the effect of industry competition. The Company's expectations for the forward-looking statements are described on pages [2], [6], and [7] hereof.
7
- Condensed Consolidated Statement of Profit or Loss Nine months ended December 31, 2018 and 2019
(Millions of Yen) | |||
Nine months | Nine months | ||
ended December 31, | ended December 31, | ||
2018 | 2019 | ||
Continuing operations | |||
Sales revenue | 2,870,415 | 2,730,767 | |
Cost of sales | (2,058,065) | (1,968,854) | |
Gross profit | 812,350 | 761,913 | |
Selling, general and administrative expenses | (564,653) | (592,896) | |
Other operating income | 16,447 | 17,610 | |
Other operating expenses | (17,696) | (36,746) | |
Share of profit of associates and joint ventures | 21,607 | 10,687 | |
Operating income | 268,055 | 160,568 | |
Financial income | 9,388 | 6,785 | |
Financial expenses | (14,244) | (22,629) | |
Income before taxes | 263,199 | 144,724 | |
Income taxes | (58,485) | (53,336) | |
Net income from continuing operations | 204,714 | 91,388 | |
Discontinued operations | |||
Net income from discontinued operations | 1,711 | 16,892 | |
Net income | 206,425 | 108,280 | |
Net income attributable to | |||
Owners of the parent | 165,988 | 76,272 | |
Non-controlling interests | 40,437 | 32,008 | |
Net income | 206,425 | 108,280 | |
Earnings per share | |||
Basic (Yen) | |||
Continuing operations | 115.47 | 41.82 | |
Discontinued operations | 1.20 | 11.89 | |
Total | 116.67 | 53.71 | |
Diluted (Yen) | |||
Continuing operations | 106.57 | 38.60 | |
Discontinued operations | 1.11 | 10.94 | |
Total | 107.68 | 49.54 |
8
- Condensed Consolidated Statement of Comprehensive Income Nine months ended December 31, 2018 and 2019
(Millions of Yen) | ||
Nine months | Nine months | |
ended December 31, | ended December 31, | |
2018 | 2019 | |
Net income | 206,425 | 108,280 |
Other comprehensive income | ||
Items that will not be reclassified to profit or loss | ||
Net gain (loss) on revaluation of financial assets | (856) | 5,593 |
measured at fair value | ||
Remeasurements of defined benefit pensions plans | (7,808) | 6,701 |
Share of other comprehensive income(loss) | ||
of associates and joint ventures for using | (12) | (143) |
the equity method |
Total items that will not be reclassified to profit or loss
Items that may be subsequently reclassified to profit or loss
Exchange differences on translation of foreign operations
Net gain (loss) on derivatives designated as cash flow hedges
Share of other comprehensive income(loss) of associates and joint ventures for using the equity method
Total items that may be subsequently reclassified to profit or loss
Total other comprehensive income (net of tax)
Total comprehensive income
Total comprehensive income attributable to Owners of the parent Non-controlling interests
(8,676)12,151
(3,484)(22,338)
(2,652)(28)
(836)(5,002)
(6,972)(27,368)
(15,648)(15,217)
190,77793,063
153,70869,247
37,06923,816
9
(3) Condensed Consolidated Statement of Financial Position
(Millions of Yen) | ||
March 31, 2019 | December 31, 2019 | |
Assets | ||
Current assets | ||
Cash and cash equivalents | 321,541 | 245,348 |
Trade receivables | 855,107 | 772,312 |
Inventories | 623,049 | 611,342 |
Other financial assets | 248,262 | 213,346 |
Other current assets | 76,072 | 110,382 |
Subtotal | 2,124,031 | 1,952,730 |
Assets held for sales | 17,810 | 9,195 |
Total current assets | 2,141,841 | 1,961,925 |
Non-current assets | ||
Property, plant and equipment | 1,683,354 | 1,743,222 |
Goodwill | 648,806 | 627,220 |
Intangible assets | 568,787 | 547,247 |
Investments accounted for using the equity method | 183,067 | 175,215 |
Other financial assets | 228,571 | 263,745 |
Other non-current assets | 33,573 | 36,172 |
Deferred tax assets | 84,509 | 58,359 |
Total non-current assets | 3,430,667 | 3,451,180 |
Total assets | 5,572,508 | 5,413,105 |
10
(Millions of Yen) | ||
March 31, 2019 | December 31, 2019 | |
Liabilities | ||
Current liabilities | ||
Trade payables | 492,404 | 457,409 |
Bonds and borrowings | 1,108,643 | 615,562 |
Income tax payable | 31,768 | 19,560 |
Other financial liabilities | 222,377 | 232,666 |
Provisions | 8,296 | 9,303 |
Other current liabilities | 138,089 | 131,518 |
Subtotal | 2,001,577 | 1,466,018 |
Liabilities directly associated with assets held for sales | 11,723 | 448 |
Total current liabilities | 2,013,300 | 1,466,466 |
Non-current liabilities | ||
Bonds and borrowings | 1,138,108 | 1,443,336 |
Other financial liabilities | 26,755 | 89,227 |
Retirement benefit liabilities | 120,816 | 109,100 |
Provisions | 28,294 | 23,254 |
Other non-current liabilities | 41,971 | 68,630 |
Deferred tax liabilities | 177,410 | 174,074 |
Total non-current liabilities | 1,533,354 | 1,907,621 |
Total liabilities | 3,546,654 | 3,374,087 |
Equity | ||
Common stock | 50,000 | 50,000 |
Additional paid-in capital | 321,477 | 322,565 |
Treasury stock | (63,560) | (63,501) |
Retained earnings | 1,073,873 | 1,100,049 |
Other components of equity | (3,843) | (17,225) |
Equity attributable to owners of the parent | 1,377,947 | 1,391,888 |
Non-controlling interests | 647,907 | 647,130 |
Total equity | 2,025,854 | 2,039,018 |
Total liabilities and equity | 5,572,508 | 5,413,105 |
11
- Condensed Consolidated Statement of Changes in Equity Nine months ended December 31, 2018
(Millions of Yen)
Common | Additional | Treasury | Retained | |
paid-in | ||||
stock | stock | earnings | ||
capital | ||||
Balance at April 1, 2018 | 50,000 | 321,111 | (43,569) | 956,946 |
Cumulative effects of changes | - | - | - | (85) |
in accounting policies | ||||
Restated balance at April 1, 2018
Net income
Other comprehensive income
Total comprehensive income
Purchase of treasury stock
Disposal of treasury stock
Cash dividends
Share-based payment transactions Share-based payment transactions of subsidiaries
Changes in interests in subsidiaries
Business combinations or business divestitures
Changes in scope of consolidation Transfer from other components of equity to retained earnings Transfer from other components
of equity to non-financial assets, etc.
50,000 | 321,111 | (43,569) | 956,861 |
- | - | - | 165,988 |
- | - | - | - |
- | - | - | 165,988 |
- | - | (20,025) | - |
- | (31) | 33 | - |
- | - | - | (52,867) |
- | 656 | - | - |
- | - | - | - |
- | (178) | - | - |
- | - | - | - |
- | - | - | (35) |
- | - | - | (4,405) |
- | - | - | - |
Total transactions with owners | - | 447 | (19,992) | (57,307) | |||||
Balance at December 31, 2018 | 50,000 | 321,558 | (63,561) | 1,065,542 | |||||
Other components of equity | |||||||||
Net gain | Remeasure- | Exchange | Net gain | ||||||
(loss) on | ments of | differences | (loss) on | Equity | |||||
revaluation | Non- | ||||||||
defined | on | derivatives | attributable | Total | |||||
of financial | Total | controlling | |||||||
benefit | translation | designated | to owners of | equity | |||||
assets | pensions | of foreign | as cash flow | the parent | interests | ||||
measured | |||||||||
plans | operations | hedges | |||||||
at fair value | |||||||||
Balance at April 1, 2018 | 51,544 | - | (50,455) | 173 | 1,262 | 1,285,750 | 633,740 | 1,919,490 | |
Cumulative effects of changes | - | - | - | - | - | (85) | (61) | (146) | |
in accounting policies | |||||||||
Restated balance at April 1, 2018
Net income
Other comprehensive income Total comprehensive income
Purchase of treasury stock Disposal of treasury stock Cash dividends
Share-based payment transactions Share-based payment transactions of subsidiaries
Changes in interests in subsidiaries
Business combinations or business divestitures
Changes in scope of consolidation
Transfer from other components of equity to retained earnings Transfer from other components
of equity to non-financial assets, etc. Total transactions with owners
Balance at December 31, 2018
51,544 | - | (50,455) | 173 | 1,262 | 1,285,665 | 633,679 | 1,919,344 |
- | - | - | - | - | 165,988 | 40,437 | 206,425 |
(140) | (6,781) | (2,717) | (2,642) | (12,280) | (12,280) | (3,368) | (15,648) |
(140) | (6,781) | (2,717) | (2,642) | (12,280) | 153,708 | 37,069 | 190,777 |
- | - | - | - | - | (20,025) | - | (20,025) |
- | - | - | - | - | 2 | - | 2 |
- | - | - | - | - | (52,867) | (33,935) | (86,802) |
- | - | - | - | - | 656 | - | 656 |
- | - | - | - | - | - | 27 | 27 |
- | - | - | - | - | (178) | 3,603 | 3,425 |
- | - | - | - | - | - | 1,451 | 1,451 |
- | - | - | - | - | (35) | (86) | (121) |
(2,376) | 6,781 | - | - | 4,405 | - | - | - |
- | - | - | 2,630 | 2,630 | 2,630 | - | 2,630 |
(2,376) | 6,781 | - | 2,630 | 7,035 | (69,817) | (28,940) | (98,757) |
49,028 | - | (53,172) | 161 | (3,983) | 1,369,556 | 641,808 | 2,011,364 |
12
Nine months ended December 31, 2019
(Millions of Yen)
Common | Additional | Treasury | Retained | ||||||
paid-in | |||||||||
stock | stock | earnings | |||||||
capital | |||||||||
Balance at April 1, 2019 | 50,000 | 321,477 | (63,560) | 1,073,873 | |||||
Net income | - | - | - | 76,272 | |||||
Other comprehensive income | - | - | - | - | |||||
Total comprehensive income | - | - | - | 76,272 | |||||
Purchase of treasury stock | - | - | (20) | - | |||||
Disposal of treasury stock | - | (77) | 79 | - | |||||
Cash dividends | - | - | - | (56,804) | |||||
Share-based payment transactions | - | 289 | - | - | |||||
Share-based payment transactions | - | - | - | - | |||||
of subsidiaries | |||||||||
Changes in interests in subsidiaries | - | (1,316) | - | - | |||||
Business combinations or business | - | 2,192 | - | - | |||||
divestitures | |||||||||
Changes in scope of consolidation | - | - | - | 351 | |||||
Transfer from other components | - | - | - | 6,357 | |||||
of equity to retained earnings | |||||||||
Total transactions with owners | - | 1,088 | 59 | (50,096) | |||||
Balance at December 31, 2019 | 50,000 | 322,565 | (63,501) | 1,100,049 | |||||
Other components of equity | |||||||||
Net gain | Remeasure- | Exchange | Net gain | ||||||
(loss) on | Equity | ||||||||
revaluation | ments of | differences | (loss) on | Non- | |||||
defined | on | derivatives | attributable | Total | |||||
of financial | Total | controlling | |||||||
benefit | translation | designated | to owners of | equity | |||||
assets | pensions | of foreign | as cash flow | the parent | interests | ||||
measured | |||||||||
plans | operations | hedges | |||||||
at fair value | |||||||||
Balance at April 1, 2019
Net income
Other comprehensive income Total comprehensive income
Purchase of treasury stock
Disposal of treasury stock
Cash dividends
Share-based payment transactions
Share-based payment transactions of subsidiaries
Changes in interests in subsidiaries
Business combinations or business divestitures
Changes in scope of consolidation
Transfer from other components of equity to retained earnings
Total transactions with owners
51,500 | - | (55,530) | 187 | (3,843) | 1,377,947 | 647,907 | 2,025,854 |
- | - | - | - | - | 76,272 | 32,008 | 108,280 |
7,463 | 5,398 | (19,788) | (98) | (7,025) | (7,025) | (8,192) | (15,217) |
7,463 | 5,398 | (19,788) | (98) | (7,025) | 69,247 | 23,816 | 93,063 |
- | - | - | - | - | (20) | - | (20) |
- | - | - | - | - | 2 | - | 2 |
- | - | - | - | - | (56,804) | (29,091) | (85,895) |
- | - | - | - | - | 289 | - | 289 |
- | - | - | - | - | - | (14) | (14) |
- | - | - | - | - | (1,316) | (172) | (1,488) |
- | - | - | - | - | 2,192 | 4,148 | 6,340 |
- | - | - | - | - | 351 | 536 | 887 |
(959) | (5,398) | - | - | (6,357) | - | - | - |
(959) | (5,398) | - | - | (6,357) | (55,306) | (24,593) | (79,899) |
Balance at December 31, 2019 | 58,004 | - | (75,318) | 89 | (17,225) 1,391,888 | 647,130 2,039,018 |
13
(5) Condensed Consolidated Statement of Cash Flow
Nine months ended December 31, 2018 and 2019
(Millions of Yen) | |||
Nine months | Nine months | ||
ended December 31, | ended December 31, | ||
2018 | 2019 | ||
Cash flows from operating activities | |||
Income before taxes | 263,199 | 144,724 | |
Income before taxes from discontinued operations | 2,290 | 25,585 | |
Depreciation and amortization | 143,533 | 179,374 | |
Share of profit of associates and joint ventures | (21,623) | (10,692) | |
Gain on share exchanges | - | (23,922) | |
Interest and dividend income | (8,328) | (6,520) | |
Interest expenses | 13,192 | 19,133 | |
(Increase) decrease in trade receivables | (6,232) | 54,654 | |
(Increase) decrease in inventories | (28,424) | 5,938 | |
Increase (decrease) in trade payables | 7,973 | (22,820) | |
Increase (decrease) in retirement benefit assets and | 770 | 558 | |
liabilities, net | |||
Other | (19,090) | 19,541 | |
Subtotal | 347,260 | 385,553 | |
Interest received | 3,332 | 2,800 | |
Dividends received | 22,895 | 22,975 | |
Interest paid | (14,124) | (17,508) | |
Income tax (paid) received, net | (82,627) | (56,083) | |
Net cash provided by (used in) operating activities | 276,736 | 337,737 | |
Cash flows from investing activities | |||
Purchase of property, plant and equipment | (163,282) | (163,357) | |
Proceeds from sales of property, plant and equipment | 6,056 | 10,836 | |
Purchase of intangible assets | (3,995) | (4,386) | |
Purchase of other financial assets | (322,771) | (342,795) | |
Proceeds from sales/redemption of other financial assets | 313,061 | 348,834 | |
Net cash outflow on acquisition of subsidiaries | (655,851) | (1,429) | |
Proceeds from sales of investments in subsidiaries | 15,274 | 2,836 | |
Payments for transfer of business | (4,748) | - | |
Net (Increase) decrease of time deposits | 4,006 | 25,054 | |
Other | (3,907) | 9,449 | |
Net cash provided by (used in) investing activities | (816,157) | (114,958) |
14
(Millions of Yen) | ||
Nine months | Nine months | |
ended December 31, | ended December 31, | |
2018 | 2019 | |
Cash flows from financing activities | ||
Net increase (decrease) in short-term borrowings | 635,380 | (465,199) |
Net increase (decrease) in commercial papers | 86,000 | (20,000) |
Proceeds from long-term borrowings | 58,790 | 399,636 |
Repayment of long-term borrowings | (78,903) | (117,842) |
Proceeds from issuance of bonds | 25,000 | 79,549 |
Redemption of bonds | (50,000) | (60,000) |
Repayment of lease liabilities | (2,857) | (22,800) |
Net (increase) decrease in treasury stock | (20,023) | (18) |
Dividends paid to owners of the parent | (52,867) | (56,804) |
Dividends paid to non-controlling interests | (33,815) | (29,105) |
Proceeds from stock issuance to non-controlling interests | 4,348 | 3 |
Other | (2,246) | (1,714) |
Net cash provided by (used in) financing activities | 568,807 | (294,294) |
Effect of exchange rate changes on cash and cash equivalents | 2,726 | (7,436) |
Net increase (decrease) in cash and cash equivalents | 32,112 | (78,951) |
Cash and cash equivalents at the beginning of the period | 277,624 | 321,541 |
Net increase (decrease) in cash and cash equivalents | 250 | 2,152 |
resulting from transfer to assets held for sales | ||
Net increase (decrease) in cash and cash equivalents | (35) | 606 |
resulting from change in scope of consolidation | ||
Cash and cash equivalents at the end of the period | 309,951 | 245,348 |
15
(6) Change in Accounting Policy
The main standard and interpretation newly applied by the Mitsubishi Chemical Holdings Group (MCHC Group) from the first quarter of fiscal 2019 is as follows.
Standard and interpretation | Overview of introduction or revision | |
Accounting standards and disclosure methods for handling leases | ||
IFRS 16 | Leases | have been revised. |
Specifically, under a single model, the financial statements must | ||
generally reflect asset usage rights and payment obligations for | ||
borrower leases exceeding 12 months. |
The adoption of IFRS 16 increased the carrying amounts of the MCHC Group's lease-related assets by ¥100.2 billion while increasing lease liabilities by ¥100.6 billion on the adoption date.
In adopting IFRS 16, the MCHC Group employed a retroactive adjustment as a transitional measure to recognize the cumulative effect retrospectively to the adoption date, though the cumulative impact is nothing.
(7) Discontinued Operations
1. Outline of Discontinued Operations
On May 14, 2019, MCHC's operating company, Life Science Institute, Inc. (LSII) came to an agreement on a strategic capital partnership with PHC Holdings Corporation (PHCHD), which is engaged in the healthcare business in Japan as well as overseas. In this agreement, it was determined that LSII would exchange all of its shares in LSI Medience Corporation (LSIM) for a part of PHCHD shares. On August 1, LSII completed the planned share exchange.
The MCHC Group, during the third quarter of fiscal 2019, has accordingly classified the earnings related to LSIM and its subsidiaries and affiliate and gain on the share exchange as discontinued operations. Figures for the same period of the previous fiscal year have been restated, with the discontinued operations presented separately.
2. Profit or Loss from Discontinued Operations | |||
(Millions of Yen) | |||
Nine months | Nine months | ||
ended December 31, | ended December 31, | ||
2018 | 2019 | ||
Revenue (*1) | 61,598 | 52,754 | |
Cost | (59,308) | (27,169) | |
Income before tax | |||
2,290 | 25,585 | ||
from discontinued operations | |||
Income tax expense (*2) | (579) | (8,693) | |
Net Income from discontinued operations | 1,711 | 16,892 |
(*1) In the nine months ended December 31, 2019, this included ¥23,922 million from gain on share exchanges.
(*2) In the nine months ended December 31, 2019, this included ¥(8,117) million from tax on gain on share exchanges.
(8) Subsequent Event
Acquisition of non-controlling interests through a tender offer etc. for shares of Mitsubishi Tanabe Pharma Corporation (MTPC)
1. Tender offer
MCHC implemented a tender offer as part of a series of transactions to acquire all of the shares of consolidated subsidiary MTPC from November 19, 2019, to January 7, 2020. The tender offer was completed, as the total number of the tendered shares was greater than the minimum number of shares to be purchased. MCHC thereby acquired 197,355 thousand shares of MTPC Common Stock for ¥396.7 billion (excluding transaction costs) on January 15, 2020, lifting MCHC's ownership of shares with voting rights from 56.4%, to 91.6%.
In addition, MCHC borrowed ¥397.2 billion short-term loans (with floating interest rates) in January 2020 in execution of this acquisition.
16
2. Demand for sale of shares
On January 17, 2020, MCHC notified MTPC that MCHC would request that non-controlling shareholders of MTPC sell all of their MTPC Common Stock. That day, MTPC resolved at its board of directors meeting to approve the demand. With the demand for sale of shares coming into effect on March 2, 2020 (scheduled), MTPC will be a wholly owned subsidiary of MCHC. Consideration for the acquisition is estimated at ¥95.1 billion.
MCHC estimates that additional paid-in capital will decrease ¥146.0 billion, with non-controlling interests decreasing by ¥348.0 billion through these transactions. These details and the final amounts are being reviewed.
To fund these transactions, MCHC plans to refinance short-term loans with long-term funds or bonds within a year, and does not envisage engaging in equity finance, such as by issuing new shares.
17
Attachments
- Original document
- Permalink
Disclaimer
Mitsubishi Chemical Holdings Corporation published this content on 06 February 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 06 February 2020 08:26:10 UTC